drugset / Trial / NCT02048943
Dovitinib Lactate, Gemcitabine Hydrochloride, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Solid Tumors or Pancreatic Cancer
Phase 1
Withdrawn
Roswell Park Cancer Institute
National Cancer Institute (NCI) · collabNovartis · collab
NaSingle-groupOpen-labelTreatment
Summary
This phase I trial studies the highest and safest doses of dovitinib lactate, paclitaxel albumin-stabilized nanoparticle formulation, and gemcitabine hydrochloride when given together. Dovitinib lactate disrupts the activity of fibroblast growth factor receptors and reduces cancer growth and spread. Gemcitabine hydrochloride and paclitaxel albumin-stabilized nanoparticle formulation are anti-cancer drugs for treating many cancer types.
Timeline
- Start
- 2015-03
- Primary completion
- 2015-11
- Completion
- —
Outcome
Outcome not reported
Stopped (Business): “Lack of funding”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dovitinib | Small molecule | — | — |
| Subject | Gemcitabine | Small molecule | — | — |
| Subject | Paclitaxel | Small molecule | — | — |